Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Philip van Doorn
Citi analyst Josh Levin on Thursday initiated or assumed coverage for 10 regional banks, with one "Buy" recommendation and two "Sell" calls.
If you want to follow the moves of a prescient group of professional investors, keep an eye on the endowments. (Stocks include XOM, VWO)
The Terrafugia Transition's price tag is almost $280,000, but that's not stopping interested buyers.
Dan Fitzpatrick examines three stocks viewed on Fast Money. Today's stocks include SBA Communications, Intel, and Microsoft.
Analysts believe an Apple-branded television set could be bigger than initially thought.
U.S. stocks slump in early trades, taking their cue from continued weakness in Europe's markets amid worries about rising yields on Spanish debt.
Senior columnist Adam Feuerstein explains why Vivus is the next big thing in biotech.
JPMorgan CEO Jamie Dimon earned $23.1 million in 2011 while Morgan Stanley has put some of its mortgage woes in its past.
Dollar stores and drug stores are the winners, while supermarkets are the losers.